NASDAQ:LGVN

Longeveron Stock Forecast, Price & News

$6.92

+0.11 (+1.62 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.53

Now: $6.92▼

$7.02

50-Day Range

$5.66

MA: $6.99▼

$8.45

52-Week Range

$5.61

Now: $6.92▼

$12.48

Volume63,398 shs

Average Volume776,738 shs

Market Capitalization$129.45 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:LGVN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.longeveron.com

Phone305 909 0840

Employees12

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares18,707,000

Market Cap$129.45 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
April 12, 2021 | finance.yahoo.com

Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 | finance.yahoo.com

Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call
March 26, 2021 | feeds.benzinga.com

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
March 19, 2021 | finance.yahoo.com

Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
March 15, 2021 | finance.yahoo.com

Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
March 11, 2021 | finance.yahoo.com

Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
March 10, 2021 | finance.yahoo.com

Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection
March 5, 2021 | finance.yahoo.com

Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
March 3, 2021 | finance.yahoo.com

Longeveron's Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect
February 24, 2021 | finance.yahoo.com

Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
February 24, 2021 | finance.yahoo.com

Longeveron Inc
February 24, 2021 | reuters.com

CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
February 19, 2021 | finance.yahoo.com

Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing
February 15, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.33 out of 5 stars

Medical Sector

1775th out of 2,011 stocks

Biotechnology Industry

114th out of 143 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Longeveron.

0.0 Community Rank

Outperform Votes
Longeveron has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Longeveron has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Longeveron and other stocks. Vote “Outperform” if you believe LGVN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LGVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Longeveron does not currently pay a dividend.
Dividend Growth
Longeveron does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Longeveron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $805.00 in company stock and sold $0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$6.92

+0.11 (+1.62 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive LGVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

Longeveron (NASDAQ:LGVN) Frequently Asked Questions

What stocks does MarketBeat like better than Longeveron?

Wall Street analysts have given Longeveron a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Longeveron wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Longeveron's key executives?

Longeveron's management team includes the following people:

Dr. Joshua Michael Hare M.D., Co-Founder, Chief Science Officer & Chairman (Age 58, Pay $270k)
Mr. Geoff Green M.B.A., Chief Exec. Officer (Age 47, Pay $234.33k)
Mr. James Clavijo, CFO & Treasurer (Age 55, Pay $171.81k)
Mr. Paul T. Lehr J.D., International Exec. Director, Gen. Counsel & Sec. (Age 53, Pay $182.65k)
Dr. Anthony Oliva Ph.D., Sr. VP of Scientific Affairs (Age 50)

Who are some of Longeveron's key competitors?

Some companies that are related to Longeveron include Silence Therapeutics (SLN), Theratechnologies (TH), Terns Pharmaceuticals (TERN), Sensei Biotherapeutics (SNSE), Pfenex (PFNX), Angion Biomedica (ANGN), BELLUS Health (BLU), NexImmune (NEXI), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), Landos Biopharma (LABP), Portage Biotech (PRTG), ProMetic Life Sciences (PLI), Synairgen (SNG), Unity Biotechnology (UBX) and Novacyt (NCYT).
View all of LGVN's competitors.

When did Longeveron IPO?

(LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

What is Longeveron's stock symbol?

Longeveron trades on the NASDAQ under the ticker symbol "LGVN."

When does the company's lock-up period expire?

Longeveron's lock-up period expires on Wednesday, August 11th. Longeveron had issued 2,660,000 shares in its public offering on February 12th. The total size of the offering was $26,600,000 based on an initial share price of $10.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Longeveron?

Shares of LGVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Longeveron's stock price today?

One share of LGVN stock can currently be purchased for approximately $6.92.

How much money does Longeveron make?

Longeveron has a market capitalization of $129.45 million.

How many employees does Longeveron have?

Longeveron employs 12 workers across the globe.

What is Longeveron's official website?

The official website for Longeveron is www.longeveron.com.

How can I contact Longeveron?

The company can be reached via phone at 305 909 0840.

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Longeveron Stock Forecast, Price & News

Adding

Adding

Adding Longeveron Inc.